Astellas Retracts EMA Application for ACP
Astellas withdraws EMA application for ACP, pledges continued efforts for GA treatment in Europe.
Astellas Pharma recently decided to pull its European Medicines Agency (EMA) application for avacincaptad pegol (ACP), a drug designed to address geographic atrophy (GA) tied to age-related macular degeneration (AMD). Although clinical trials showed ACP could slow GA progression, discussions with EMA presented unexpected challenges, leading to this decision.
Despite the setback, Astellas reaffirmed its commitment to advancing ACP globally, including within Europe, where it will continue exploring other regulatory pathways. This reflects Astellas’ dedication to bringing innovative treatment options to patients who are grappling with the progressive vision loss that GA causes.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Mehr aus Pharma News
Alle Beiträge →
Curia New York erhält FDA-Warnschreiben wegen Tausender undokumentierter chromatographischer Injektionen
Ab Science überarbeitet Studienzeitpläne nach drei GCP-Inspektionen
Discussion